Summary

• Page properties (2 modified, 0 added, 0 removed)
• Objects (0 modified, 1 added, 0 removed)
  • XWiki.XWikiComments[0]

Details

Page properties

Tags

...	...	@@ -1,0 +1,1 @@
	1	+IN:JUBLPHARMA

Content

...	...	@@ -4,7 +4,7 @@
4	4
5	5	= Company Overview =
6	6
7		-Pharmova is born out of a combination of ‘Pharma’ and ‘Nova’ (New) and Jubilant Pharmova Limited will continue to focus on offering products and services with, excellence in research and manufacturing, catering to the unmet health needs at an affordable price. {{footnote}}https://www.jubilantpharmova.com{{/footnote}}
	7	+Jubilant Pharmova Limited (NSE: JUBLPHARMA) Pharmova is born out of a combination of ‘Pharma’ and ‘Nova’ (New) and Jubilant Pharmova Limited will continue to focus on offering products and services with, excellence in research and manufacturing, catering to the unmet health needs at an affordable price. {{footnote}}https://www.jubilantpharmova.com{{/footnote}}
8	8
9	9
10	10	It is an integrated global pharmaceuticals company having three business segments Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs.
...	...	@@ -22,6 +22,10 @@
22	22	Jubilant Pharmova Limited has a team of around 7,700 multicultural people across the globe and is committed to delivering value to its customers in over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies worldwide.
23	23
24	24
	25	+[[image:JUBLPHARMA1.png]]
	26	+
	27	+{{putFootnotes/}}
	28	+
25	25	= Business Segments =
26	26
27	27	== Pharmaceuticals ==
...	...	@@ -53,7 +53,7 @@
53	53	One of the market leaders in the United States, based on market share of several key products
54	54
55	55
56		-== Contract Research and Development Services ==
	60	+== Contract R&D Services ==
57	57
58	58	Jubilant Biosys Ltd is a part of the Jubilant Pharmova family of companies with R&D centers in India and business offices in Asia and North America. With its global reach, Jubilant Biosys provides comprehensive drug discovery services and contract research services–from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared)–in partnership with leading worldwide healthcare companies. {{footnote}}https://www.jubilantbiosys.com/about-us/company-overview/{{/footnote}}
59	59
...	...	@@ -73,9 +73,9 @@
73	73	* Synthetic & Developmental Chemistry
74	74	* Pharmacology
75	75
76		-
77	77	Jubilant Biosys collaborates with the world’s leading pharmaceutical, biotech companies, academic institutions and research foundations.
78	78
	82	+{{putFootnotes/}}
79	79
80	80	== Proprietary Novel Drugs ==
81	81
...	...	@@ -106,6 +106,9 @@
106	106	The global crop protection chemicals market size was US$ 58.4 billion in 2019 and is anticipated to expand at a CAGR of 3.3% from 2020 to 2027. Greater emphasis on high crop output to counter food security is the key growth driver.
107	107
108	108
	113	+[[image:JUBLPHARMA2.png]]
	114	+
	115	+
109	109	= Financial Overview =
110	110
111	111
...	...	@@ -134,6 +134,9 @@
134	134	The Drug Discovery & Development Solutions (DDDS) segment includes its Drug Discovery Services (Jubilant Biosys Limited and Jubilant Chemsys Limited) & Proprietary Drug Discovery (Jubilant Therapeutics Inc.) businesses. Revenues in FY 2020 were at Rs 2,615 million as compared to Rs 2,168 million in the previous year, up 21% YoY.
135	135
136	136
	144	+[[image:JUBLPHARMA3.png]]
	145	+
	146	+
137	137	== FY21 results ==
138	138
139	139

XWiki.XWikiComments[0]

Date

...	...	@@ -1,0 +1,1 @@
	1	+2021-06-15 06:06:08.502

Author

...	...	@@ -1,0 +1,1 @@
	1	+XWiki.AsifF

Comment

...	...	@@ -1,0 +1,2 @@
	1	+Recent investor presentation
	2	+https://www.jubilantpharmova.com/Uploads/image/1654imguf_JLL-InvestorPresentationNovember2020.pdf